Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis
Insurance coverage is an important determinant of treatment choice in irritable bowel syndrome. A multilevel microsimulation tracked costs and outcomes among 10 million hypothetical patients with IBS. Routinely using global IBS treatments before US Food and Drug Administration-approved drug therapies resulted in per-patient cost savings of $9,034.59 for IBS-D. Health outcomes were similar, regardless of treatment sequence.
